Trasylol

Trasylol is a medication administered by injection to reduce bleeding during complex surgery, such as heart and liver surgery

(), manufactured by , is a protein that is used as medication administered by injection to reduce bleeding during complex surgery, such as heart and liver surgery. Its main effect is the slowing down of fibrinolysis, the process that leads to the breakdown of blood clots. The purpose of is to decrease the need for blood transfusions during surgery, as well as end-organ damage due to hypotension (low blood pressure) as a result of marked blood loss.

withholds critical information

In September 2006, Pharmaceuticals was faulted by the for not revealing during testimony the existence of a commissioned study of that concluded carried greater risks. The was alerted to the study by one of the researchers involved.

recall

The drug was temporarily withdrawn worldwide in 2007 after studies suggested that its use increased the risk of complications or death; after this was confirmed by follow-up studies, was entirely and permanently recalled in May 2008, except – at least for the time being – for very restricted research use.

Do you have a claim?

If you or your loved one has suffered a serious injury or death as a result of , you may be entitled to compensation for medical expenses, loss of wages, and pain and suffering.

Please contact our trasylol lawyers today by filling out the brief questionnaire, or by calling our toll free number () for a free, no-cost, no-obligation legal evaluation of your case.

Latest News

Follow-up to Canadian BART study confirms Trasylol risks

A report released yesterday underlines the danger of Trasylol (), which was used for years to limit bleeding during surgery. was taken off the market last year after U.S. tests indicated the drug posed a significantly higher risk of death as opposed to other anti-bleeding drugs.

The new study, as reported by Forbes.com, includes an examination of use in 49 randomized clinical trials, and also includes new information from the Blood Conservation Using Antifibrinolytics in a Randomized Trial (BART) study, published earlier this year. The findings of the new study, which was conducted by Canadian and Australian reserachers, will be published in the Jan. 20 issue of the Canadian Medical Association Journal.

Read the rest of this entry »

Pre-emption could give Bayer an escape from Trasylol case

Zero accountability for drug companies?

Bloomberg recently ran an article about pharmaceutical companies enjoying their “get out of jail free cards” — revisions to regulations that favor the rights of pharmaceutical companies over consumers who use their drugs. The revised regulations, written just after George W. Bush’s second inauguration in 2005, allow federal law to trump state law, thereby clearing the path for drug manufacturers to develop, test, market, and essentially do business with impunity from the law.

Read the rest of this entry »

Zero accountability for drug companies?

Bloomberg recently ran an interesting and comprehensive article about pharmaceutical companies enjoying their “get out of jail free cards” — revisions to regulations that favor the rights of pharmaceutical companies over consumers who use their drugs. The revised regulations, written just after George W. Bush’s inauguration in 2005, allow federal law to trump (or pre-empt) state law, thereby clearing the path for drug manufacturers to develop, test, market, and essentially do business with impunity from the law.

Read the rest of this entry »